STOCK TITAN

Cv Sciences Stock Price, News & Analysis

CVSI OTC

Welcome to our dedicated page for Cv Sciences news (Ticker: CVSI), a resource for investors and traders seeking the latest updates and insights on Cv Sciences stock.

CV Sciences, Inc. (CVSI) operates at the intersection of scientific innovation and natural wellness, developing hemp-derived supplements and plant-based nutrition solutions. This page serves as the definitive source for official company announcements, research breakthroughs, and operational developments.

Investors and industry stakeholders will find curated updates spanning regulatory milestones, product launches, and peer-reviewed studies validating CVSI's formulations. The archive includes earnings reports, manufacturing expansions, and clinical trial outcomes supporting their +PlusCBD and Cultured Foods brands.

All content undergoes rigorous verification to ensure alignment with financial disclosure standards and scientific accuracy. Users can efficiently track the company's progress in obtaining self-affirmed GRAS statuses, scaling global distribution networks, and advancing pet wellness innovations.

Bookmark this resource for real-time access to CV Sciences' advancements in cannabinoid research, nutraceutical safety protocols, and strategic partnerships within the consumer health sector. Regularly updated to reflect the company's evolving role in science-driven wellness solutions.

Rhea-AI Summary

CV Sciences (OTCQB:CVSI) has acquired Elevated Softgels, a GMP-certified and FDA-registered manufacturer of encapsulated softgels and tinctures. Elevated Softgels' flexible production capabilities allow CV Sciences to in-source production of key products, potentially leading to significant cost savings. The acquisition involves a total consideration of up to $1,000,000, including a cash payment of $100,000, shares valued at $700,000, and up to $200,000 in performance-based earn-outs. Elevated Softgels, now a wholly-owned subsidiary, is expected to contribute to immediate growth and long-term shareholder value.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.19%
Tags
-
Rhea-AI Summary

CV Sciences, Inc. will announce its first-quarter 2024 financial results on May 14, 2024. The company specializes in hemp extracts and natural products. The conference call with the investment community will take place at 7:00 a.m. Pacific Time on the same day. Interested investors can access the webcast on the Investor Relations section of the company's website, and a telephone replay will be available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.41%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.13%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.32%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.6%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.9%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.07%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.65%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.73%
Tags

FAQ

What is the current stock price of Cv Sciences (CVSI)?

The current stock price of Cv Sciences (CVSI) is $0.0488 as of December 23, 2025.

What is the market cap of Cv Sciences (CVSI)?

The market cap of Cv Sciences (CVSI) is approximately 5.5M.
Cv Sciences

OTC:CVSI

CVSI Rankings

CVSI Stock Data

5.53M
184.23M
0.02%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States
San Diego